Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Wednesday morning, MarketBeat.com reports. The firm currently has a $455.00 target price on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Wells Fargo & Company reduced their price objective on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a report on Friday, August 14th. Truist Financial dropped their price target on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Stifel Nicolaus reduced their price target on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Finally, Chardan Capital restated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $386.14.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $266.11 on Wednesday. The firm has a market cap of $35.61 billion, a P/E ratio of 49.46 and a beta of 0.31. Alnylam Pharmaceuticals has a twelve month low of $197.81 and a twelve month high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The company has a 50 day moving average of $259.25 and a 200 day moving average of $291.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter last year, the company earned ($0.51) EPS. The company’s quarterly revenue was up 66.9% compared to the same quarter last year. As a group, research analysts expect that Alnylam Pharmaceuticals will post 6.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. MV Capital Management Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $25,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $27,000. Golden State Wealth Management LLC increased its holdings in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. Finally, Manchester Capital Management LLC raised its position in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.